HomeCompareALTAF vs ABBV

ALTAF vs ABBV: Dividend Comparison 2026

ALTAF yields 20000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ALTAF wins by $52481917574412746752.00M in total portfolio value
10 years
ALTAF
ALTAF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full ALTAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ALTAF vs ABBV

📍 ALTAF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodALTAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ALTAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ALTAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ALTAF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ALTAF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ALTAF + ABBV for your $10,000?

ALTAF: 50%ABBV: 50%
100% ABBV50/50100% ALTAF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ALTAF
No analyst data
Altman Z
-28.6
Piotroski
0/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ALTAF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricALTAFABBV
Forward yield20000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$52481917574412746752.00M$102.3K
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$24,771.77
Total dividends collected$52448189483771600896.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ALTAF vs ABBV ($10,000, DRIP)

YearALTAF PortfolioALTAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,550$430.00+$2.00MALTAF
2$377,983,225$375,831,775.70$13,472$627.96+$377.97MALTAF
3$66,433,479,469$66,029,037,418.28$15,906$926.08+$66433.46MALTAF
4$10,916,985,471,987$10,845,901,648,955.73$19,071$1,382.55+$10916985.45MALTAF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$23,302$2,095.81+$1677384363.75MALTAF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$29,150$3,237.93+$240985175079.11MALTAF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$37,536$5,121.41+$32373573631143.66MALTAF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$50,079$8,338.38+$4066766648320630.00MALTAF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$69,753$14,065.80+$477730483406513344.00MALTAF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$102,337$24,771.77+$52481917574412746752.00MALTAF

ALTAF vs ABBV: Complete Analysis 2026

ALTAFStock

Morella Corporation Limited, an exploration and resource development company, focuses on the exploration and development of lithium and battery minerals in Australia and the United States. It operates through Exploration Services and Mineral Exploration segments. The company holds a 51% interest in the Mallina Lithium Project located within the northern Pilbara, Western Australia; and a 60% interest and right to acquire a 100% interest in the Fish Lake Valley Lithium Project located in Esmeralda County, west-central Nevada, the United States. It also provides drilling services primarily to mining and exploration companies. The company was formerly known as Altura Mining Limited and changed its name to Morella Corporation Limited in December 2021. Morella Corporation Limited was incorporated in 2000 and is based in West Perth, Australia.

Full ALTAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ALTAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ALTAF vs SCHDALTAF vs JEPIALTAF vs OALTAF vs KOALTAF vs MAINALTAF vs JNJALTAF vs MRKALTAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.